Product Pipeline

Today, Parkinson’s disease care depends on clinical observation, which can be subjective and time-consuming. ANLIVA® Eye Movement aims to use eye-tracking sensors for fast, objective assessments of treatment response. Our goal is to enhance clinical decision-making with digital biomarkers to support evaluation and tracking of disease progression.

Clinical trials in collaboration with Dartmouth-Hitchcock Clinic (USA) are underway, with FDA 510(k) clearance targeted for the end of 2026. Potential for early detection. Patent pending.

Deep Brain Stimulation (DBS) is a well-established therapy for late-stage Parkinson’s disease. Calibrating DBS settings can be both complex and time-consuming. ANLIVA® Deep Brain Stimulation aims for optimizing signal programming. Our solution creates a digital twin of the patients brain to predict treatment response and suggest optimal settings.

Clinical trials in collaboration with Dartmouth-Hitchcock Clinic (USA) are underway, with FDA 510(k) clearance targeted for the end of 2026. DBS vendor-agnostic solution. Patent pending.

Psilmi® is being developed through a partnership-first approach, bringing together clinical expertise, eye-tracking technology and digital biomarker analysis. Our strategy is to work with academic, clinical and industry partners to address unmet needs, co-develop targeted applications and build the evidence required for clinical use.

Our ambition is to help clinicians better understand conditions with overlapping symptoms and make more informed decisions about diagnosis and care. Potential applications span autism, ADHD, depression, anxiety and other neuropsychiatric conditions, with each application developed and validated for its specific clinical purpose.

Co-development with Uppsala University (Sweden) forms part of this approach. We welcome additional partners to explore new applications, contribute clinical expertise and advance Psilmi® through research, validation and regulatory development.